Inventor · disambiguated record
Karen Chu
Also filed as: CHU KAREN · CHU KAREN W
7 granted patents·15 pending applications·68 citations·filing 2001–2025
83Inventor score
Top patents by PatentIndex Score
22 records- 0188US10973879B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Apr 13, 2021·5 cites·21 claims
- 0284US6797642B1Method to improve barrier layer adhesionNOVELLUS SYSTEMS INC·Filed 2002·Granted Sep 28, 2004·42 cites·16 claims
- 0376US10968278B2Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using sameSANOFI BIOTECHNOLOGY·Filed 2016·Granted Apr 6, 2021·3 cites·24 claims
- 0472US7214368B2Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-α transgeneGENVEC INC·Filed 2002·Granted May 8, 2007·9 cites·16 claims
- 0566US12280093B2Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathyREGENERON PHARMA·Filed 2021·Granted Apr 22, 2025·0 cites·33 claims
- 0666US11071780B2Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumabREGENERON PHARMA·Filed 2018·Granted Jul 27, 2021·0 cites·9 claims
- 0764US7199048B2Method for preventing metalorganic precursor penetration into porous dielectricsNOVELLUS SYSTEMS INC·Filed 2004·Granted Apr 3, 2007·9 cites·19 claims
- 0861US2025268983A1Use of a VEGF Antagonist to Treat Angiogenic Eye DisordersREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0957US2025025531A1Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye DisordersREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1055US2012203052A1Therapeutic regimen for treating cancerRASMUSSEN HENRIK S·Filed 2012·Application pending·0 cites
- 1155US2024024420A1Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye DisordersREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1254US2007166284A1Therapeutic regimen for treating cancerGENVEC INC·Filed 2007·Application pending·0 cites
- 1354US2010305199A1Therapeutic regimen for treating cancerGENVEC INC·Filed 2010·Application pending·0 cites
- 1453US2023295266A1Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye DisordersREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1553US2012123186A1Therapeutic regimen for treating cancerKESSLER PAUL D·Filed 2011·Application pending·0 cites
- 1652US2023302085A1Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye DisordersREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1751US2006257369A1Therapeutic regimen for treating cancerGENVEC INC·Filed 2006·Application pending·0 cites
- 1850US2021301027A1Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using sameSANOFI BIOTECHNOLOGY·Filed 2021·Application pending·0 cites
- 1949US2017080086A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 2048US2011034752A1Therapeutic regimen for treating cancerGENVEC INC·Filed 2010·Application pending·0 cites
- 2146US2016144025A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 2245US2003086903A1Therapeutic regimen for treating cancerGENVEC INC·Filed 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →